Speaker illustration

Professor Chris Pemberton

University of Otago Christchurch, Christchurch (New Zealand)

Member of:

European Society of Cardiology

Research Professor at Christchurch Heart Institute, University of Otago, Christchurch, New Zealand. Director of Translational Biodiscovery Laboratory, with interests in novel biomarker discovery, assay technologies and bioactivity of new vasoactive agents. Also, Chief Scientific Officer of Upstream Medical Technologies, a diagnostic biomarker company based in New Zealand. http://www.upstreamdx.com/

The signal peptide of CNP is a novel predictor of MI, MACE and bleeding risk in chest pain patients

Event: ESC CONGRESS 2019

Topic: Biomarkers

Session: Clinical risk factors, prevalence and prognosis

Thumbnail

The protein APRIL predicts adverse outcomes in DAPT patients better than NT-proBNP and troponin

Event: ESC CONGRESS 2019

Topic: Biomarkers

Session: Acute Coronary Syndromes: Biomarkers

Thumbnail

BNP signal peptide protects the heart from ischemia-reperfusion injury

Event: ESC Congress 2018

Topic: Ischaemia, Infarction, Cardioprotection

Session: Late Breaking Basic and Translational Science - Cardiac Biology

Thumbnail

The TNF receptor TACI is a novel inflammatory predictor of heart failure

Event: ESC Congress 2018

Topic: Biomarkers

Session: Chronic heart failure – Diagnostic methods

Thumbnail

Prognostic performance of APRIL, a TNF alpha family protein, in acutely breathless patients.

Event: ESC CONGRESS 2017

Topic: Biomarkers

Session: Prevention general

Thumbnail

This platform is supported by

logo Novo Nordisk